Richard Saynor
Previously, Saynor was Senior Vice President, Classic and Established Products (CEP) at GSK from 13 September 2010. As SVP, CEP, he was responsible for driving top-line sales, leveraging the supply chain and maximising operating profit for post-patent products spanning six therapy areas (Respiratory, Allergy, Anti-infective, Neuroscience, Dermatology and Urology).
Richard brings with him over 20 years of experience in the Generics and Pharma industry. He has held senior leadership positions internationally and is well-versed in managing complex and diverse regions within the emerging markets of Latam and Asia, as well as more established markets in Europe and Canada.
A qualified Pharmacist, Richard graduated from Bradford University with a Bachelor of Pharmacy and is a member of the Royal Pharmaceutical Society.
Articles: Richard Saynor
Improving Health Literacy with Artificial Intelligence
AI / GSK’s Richard Saynor outlines the ways in which an increased embrace of technologies which utilise artificial intelligence can help improve health literacy and therefore patient outcomes. In healthcare, AI has the potential to improve drug discovery, development and manufacturing, and enhance interactions with customers, doctors and patients As a healthcare company, a big part…
How Can Pharma Progress the Sustainable Development Goals?
Opinion / Richard Saynor, Senior Vice President, Classic and Established Products at GSK urges big pharma to weigh in on improving global health and well-being to achieve the United Nations Sustainable Development Goals. On the part of pharmaceutical companies, we have a responsibility to help people gain access to high-quality healthcare and the medicines that they need,…
Latest Report
